B-cell epitope peptide vaccination targeting dimer interface of epidermal growth factor receptor (EGFR)

Immunology Letters

Volumn 153, Issue 1-2, 2013, Pages 33-40

  Zhu, Lei ^a,b   Zhao, Lin ^a   Wu, Meizhi ^a   Chen, Zhange ^a   Li, Huangjin ^a  

^a GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

Author keywords

B cell epitope; Dimerization; Vaccine

Indexed keywords

DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITOPE; HYBRID PROTEIN; IMMUNOGLOBULIN; PEPTIDE VACCINE; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; LEWIS CARCINOMA; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RABBIT; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

B-CELL EPITOPE; DIMERIZATION; ECD; EGF; EGFR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EXTRACELLULAR DOMAIN.; HER-2; HER-3; HER-4; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 3; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 4; MEASLES VIRUS FUSION PROTEIN; MVF; TGFΑ; TRANSFORMING GROWTH FACTOR Α; VACCINE;

ANIMALS; ANTIBODIES; CANCER VACCINES; CELL LINE, TUMOR; DIMERIZATION; ENZYME ACTIVATION; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; RABBITS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VACCINATION;

EID: 84881240568     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2013.07.003     Document Type: Article

References (44)

1. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990, 61:203-212.
2. Yarden Y., Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
3. Lemmon M.A., Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010, 141:1117-1134.
4. Hunter T. Signaling-2000 and beyond. Cell 2000, 100:113-127.
5. Ke L.D., Adler-Storthz K., Clayman G.L. Differential expression of epidermal growth factor receptor in human head and neck cancers. Head Neck 1998, 20:320-327.
6. Gorgoulis V., Aninos D., Mikou P. Expression of EGF, TGF-alpha and EGFR in squamous cell lung carcinomas. Anticancer Res 1992, 12:1183-1187.
7. Libermann T.A., Nusbaum H.R., Razon N. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985, 313:144-147.
8. Salomon D.S., Brandt R., Ciardiello F. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19:183-232.
9. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002, 4:2-8.
10. Siwak D.R., Carey M., Hennessy B.T. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010, 2010:568938.
11. Herbst R.S., Bunn P.A. Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 2003, 9:5813-5824.
12. Voelzke W.R., Petty W.J., Lesser G.J. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr Treat Options Oncol 2008, 9:23-31.
13. Scaltriti M., Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006, 12:5268-5272.
14. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
15. Van Cutsem E., Köhne C.H., Hitre E. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
16. Douillard J.Y., Siena S., Cassidy J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705.
17. Correale P., Marra M., Remondo C. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 2010, 46:1703-1711.
18. Fearon E.R. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011, 6:479-507.
19. Souglakos J., Philips J., Wang R. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 2009, 101:465-472.
20. Troiani T., Zappavigna S., Martinelli E. Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. Expert Opin Biol Ther 2013, 13:241-255.
21. Caraglia M., Santini D., Bronte G. Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules. Curr Drug Metab 2011, 12:944-955.
22. Garrett T.P., McKern N.M., Lou M. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002, 110:763-773.
23. Ogiso H., Ishitani R., Nureki O. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002, 110:775-787.
24. Burgess A.W., Cho H.S., Eigenbrot C. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 2003, 12:541-552.
25. Cho H.S., Leahy D.J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 2002, 297:1330-1333.
26. Ferguson K.M., Berger M.B., Mendrola J.M. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 2003, 11:507-517.
27. Schlessinger J. Signal transduction. Autoinhibition control. Science 2003, 300:750-752.
28. Moscatello D.K., Holgado-Madruga M., Emlet D.R. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 1998, 273:200-206.
29. Hughes J.B., Berger C., Rødland M.S. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther 2009, 8:1885-1892.
30. Johns T.G., Adams T.E., Cochran J.R. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004, 279:30375-30384.
31. Kaumaya, Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes; 2010, US7691396.
32. Allen S.D., Garrett J.T., Rawale S.V. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007, 179:472-482.
33. Dakappagari N.K., Douglas D.B., Triozzi P.L. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 2000, 60:3782-3789.
34. Saha S., Raghava G.P.S. BcePred: prediction of continuous B-cell epitopes in antigenic sequences using physico-chemical properties. Artificial Immune Systems 2004, 197-204. Springer-Verlag Berlin Heidelberg Inc., Berlin. G. Nicosia, V. Cutello, P.J. Bentley, J. Timis (Eds.).
35. Wu M., Zhao L., Zhu L. Expression and purification of chimeric peptide comprising EGFR B-cell epitope and measles virus fusion protein T-cell epitope in Escherichia coli. Protein Expr Purif 2012, 88:7-12.
36. Pines G., Huang P.H., Zwang Y. EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene 2010, 29:5850-5860.
37. Sakai K., Yokote H., Murakami-Murofushi K. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci 2007, 98:1498-1503.
38. Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002, 110:669-672.
39. Lu C., Mi L.Z., Grey M.J. Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. Mol Cell Biol 2010, 30:5432-5443.
40. Zhang X., Gureasko J., Shen K. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
41. Luwor R.B., Johns T.G., Murone C. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res 2001, 61:5355-5361.
42. Baselga J., Cortés J., Kim S.B. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
43. Gianni L., Pienkowski T., Im Y.H. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012, 13:25-32.
44. Sims A.H., Zweemer A.J., Nagumo Y. Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer. Br J Cancer 2012, 106:1779-1789.